Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Taylor Swift may be signed to the label, but Universal Music Group somehow can’t find a way to make its business work.
A patent for generative neural network-based ultrasounds from medical device firm Philips could provide more data to develop AI innovations throughout…
Pfizer, Moderna, and GlaxoSmithKline are developing vaccines for RSV to fill the gap on their balance sheets.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Shell has started to shop around for buyers to offload its stake in an offshore wind project off the coast of Scotland.
Ryanair said it had seen its profits take a 46% nosedive, and would have to offer “materially lower” airfares for the busy summer period.
After years of spending big with little to show for it, Apple is attempting to rein in costs at Apple TV+.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Activist investing firm Elliott Management has taken a significant stake in Starbucks, and has already begun pushing for strategic changes.
Just two years after the mega-merger that brought Warner Bros. and Discovery together, it’s discussing dramatic plans to break up.
Anglo American is cutting back diamond production to try to hedge against China’s continued ambivalence toward the gemstones.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.